KIORA PHARMACEUTICALS INC(KPRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $16.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
KPRX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for KIORA PHARMACEUTICALS INC (KPRX), a Healthcare sector company. KPRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $16.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), KIORA PHARMACEUTICALS INC reports net income of $-2.4M, free cash flow of $-3.2M. Top institutional holders of KPRX by reported 13-F value include ADAR1 Capital Management,, CITADEL ADVISORS, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. KPRX trades on the Nasdaq exchange and files with the SEC under CIK 1372514. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KIORA PHARMACEUTICALS INC directly from SEC EDGAR.
Net Income
Q1 2026
$-2.4M
Free Cash Flow
Q1 2026
$-3.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-100.0% YoYNet Income
-301495.1% YoYOperating Income
-384.5% YoYEPS (Diluted)
-403.4% YoYTotal Assets
-33.5% YoYTotal Debt
Op. Cash Flow
-216.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 -100.0% | $16.0M | $0.00 | — | $0.00 -100.0% | $2.7M |
| Net Income | $-10.8M -301495.1% | $3.6K +128.7% | $-12.5K +99.9% | $-13.6M +1.4% | $-13.8M -94.0% | $-7.1M |
| Operating Income | $-12.8M -384.5% | $4.5M +135.8% | $-12.6M -2.3% | $-12.3M +13.5% | $-14.2M | — |
| EPS (Diluted) | $-2.64 -403.4% | $0.87 +103.6% | $-24.25 -30.7% | $-18.55 +67.5% | $-57.12 | — |
| Total Assets | $24.3M -33.5% | $36.5M +166.1% | $13.7M -26.6% | $18.7M -7.2% | $20.1M +99.1% | $10.1M |
| Total Debt | — | — | — | — | — | $0.00 |
| Operating Cash Flow | $-10.0M -216.4% | $8.6M +189.6% | $-9.6M +8.4% | $-10.4M +2.3% | $-10.7M -30.9% | $-8.2M |
AI Insight: KPRX Ratio Trends
KPRX's return metrics collapsed in Q1 2026, with ROE at -69.4% and ROIC at -72.1%, reversing a brief Q3 2025 breakeven and signaling persistent capital destruction.
• ROE deteriorated sharply from 0.5% in Q3 2025 to -69.4% in Q1 2026, erasing the only positive quarter in the dataset.
• ROIC swung from -14.2% in Q3 2025 to -72.1% in Q1 2026, the second-worst quarterly reading observed.
• TTM ROE of -79.4% and ROIC of -93.4% reflect sustained, deep capital destruction over the trailing twelve months.
⚠ Q4 2025 ROE of -161.6% suggests a severe one-off loss event; nature and recurrence risk warrant close scrutiny.
⚠ OpMargin and D/E are entirely absent across all periods, limiting visibility into operating efficiency and leverage.
Get alerted when KPRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for KIORA PHARMACEUTICALS INC including:
Top Institutional Holders of KPRX
ADAR1 Capital Management, LLC
$324.1K167,941 shCITADEL ADVISORS LLC
$95.6K49,533 shGEODE CAPITAL MANAGEMENT, LLC
$92.3K47,850 shVANGUARD CAPITAL MANAGEMENT LLC
$38.3K19,861 shXTX Topco Ltd
$28.4K14,719 shVANGUARD FIDUCIARY TRUST CO
$25.1K13,030 shTWO SIGMA SECURITIES, LLC
$23.2K12,019 shRangeley Capital, LLC
$19.3K10,000 shMORGAN STANLEY
$2.7K1,408 shUBS Group AG
$2.5K1,301 sh
| Fund | Value | Shares |
|---|---|---|
| ADAR1 Capital Management, LLC | $324.1K | 167,941 |
| CITADEL ADVISORS LLC | $95.6K | 49,533 |
| GEODE CAPITAL MANAGEMENT, LLC | $92.3K | 47,850 |
| VANGUARD CAPITAL MANAGEMENT LLC | $38.3K | 19,861 |
| XTX Topco Ltd | $28.4K | 14,719 |
| VANGUARD FIDUCIARY TRUST CO | $25.1K | 13,030 |
| TWO SIGMA SECURITIES, LLC | $23.2K | 12,019 |
| Rangeley Capital, LLC | $19.3K | 10,000 |
| MORGAN STANLEY | $2.7K | 1,408 |
| UBS Group AG | $2.5K | 1,301 |
More Healthcare Companies
View all Healthcare →Put KPRX on your watchlist
Track score changes the day KIORA PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KPRX a good stock to buy?
13F Pro's AI-powered analysis of KIORA PHARMACEUTICALS INC (KPRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KPRX are available on the KPRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own KPRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KPRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of KIORA PHARMACEUTICALS INC's investment landscape.